These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18199566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
    Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L, DIGAMI 2 Investigators.
    Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intensive glucose lowering treatment in type 2 diabetes.
    Preiss D, Ray KK.
    BMJ; 2011 Jul 26; 343():d4243. PubMed ID: 21791496
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Type 2 diabetes mellitus and coronary heart disease].
    Brändle M, Amann FW, Salomon F.
    Schweiz Med Wochenschr; 1999 May 08; 129(18):700-6. PubMed ID: 10407943
    [Abstract] [Full Text] [Related]

  • 8. [Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].
    Gustafsson I, Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt PR, MacLeod K, Laakso M, Torp-Pedersen CT, Waldenström A, DIGAMI-2 investigatorerne.
    Ugeskr Laeger; 2006 Feb 06; 168(6):581-4. PubMed ID: 16476220
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
    Mellbin LG, Malmberg K, Waldenström A, Wedel H, Rydén L, DIGAMI 2 investigators.
    Heart; 2009 May 06; 95(9):721-7. PubMed ID: 19029171
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
    MMW Fortschr Med; 2002 May 02; 144(18):65. PubMed ID: 12422717
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide).
    Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA.
    Eur Heart J; 2000 Feb 02; 21(3):220-9. PubMed ID: 10639304
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interplay of diabetes and coronary heart disease on cardiovascular mortality.
    Boccara F, Cohen A.
    Heart; 2004 Dec 02; 90(12):1371-3. PubMed ID: 15547003
    [Abstract] [Full Text] [Related]

  • 19. Diabetes, coronary heart disease and sulphonylureas-not the final word.
    Betteridge DJ, Close L.
    Eur Heart J; 2000 May 02; 21(10):790-2. PubMed ID: 10781346
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.